Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

T^{3} Stern-Gerlach Matter-Wave Interferometer.

Amit O, Margalit Y, Dobkowski O, Zhou Z, Japha Y, Zimmermann M, Efremov MA, Narducci FA, Rasel EM, Schleich WP, Folman R.

Phys Rev Lett. 2019 Aug 23;123(8):083601. doi: 10.1103/PhysRevLett.123.083601.

PMID:
31491196
2.

Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.

Ram R, Amit O, Zuckerman T, Gurion R, Raanani P, Bar-On Y, Avivi I, Wolach O.

Ann Hematol. 2019 Aug;98(8):1927-1932. doi: 10.1007/s00277-019-03719-6. Epub 2019 Jun 11.

PMID:
31187237
3.

Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.

Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U.

Haematologica. 2019 Sep;104(9):1798-1803. doi: 10.3324/haematol.2018.203869. Epub 2019 Feb 7.

4.

Hematological malignancies during pregnancy.

Barzilai M, Avivi I, Amit O.

Mol Clin Oncol. 2019 Jan;10(1):3-9. doi: 10.3892/mco.2018.1759. Epub 2018 Nov 8. Review.

5.

Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

de Kraker MEA, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, Nikolakopoulos S, Amit O, Ashton T, Beyersmann J, Held L, Lovering AM, MacGowan AP, Mouton JW, Timsit JF, Wilson D, Wolkewitz M, Bettiol E, Dane A, Harbarth S; COMBACTE-NET Consortium.

Clin Infect Dis. 2018 Nov 28;67(12):1922-1931. doi: 10.1093/cid/ciy516.

6.

Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.

Ram R, Halavy Y, Amit O, Paran Y, Katchman E, Yachini B, Kor S, Avivi I, Ben-Ami R.

Clin Infect Dis. 2018 Sep 28;67(8):1153-1160. doi: 10.1093/cid/ciy258.

PMID:
29608680
7.

Autologous Hematopoietic Cell Transplantation for Dialysis-Dependent Myeloma: More Efficient, Less Toxic.

Amit O, Ram R.

Acta Haematol. 2018;139(2):104-105. doi: 10.1159/000486890. Epub 2018 Feb 7. No abstract available.

8.

Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.

Davidov M, Perry C, Herishanu Y, Sarid N, Rom E, Amit O, Eshel R, Naparstek E, Avivi I, Ram R.

Ann Hematol. 2018 Mar;97(3):459-466. doi: 10.1007/s00277-017-3192-6. Epub 2017 Nov 25.

PMID:
29177562
9.

Fifteen years of cold matter on the atom chip: promise, realizations, and prospects.

Keil M, Amit O, Zhou S, Groswasser D, Japha Y, Folman R.

J Mod Opt. 2016 Oct 10;63(18):1840-1885. Epub 2016 May 16.

10.

The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma.

Perry C, Lerman H, Joffe E, Sarid N, Amit O, Avivi I, Kesler M, Ben-Ezra J, Even-Sapir E, Herishanu Y.

Medicine (Baltimore). 2016 Mar;95(9):e2910. doi: 10.1097/MD.0000000000002910.

11.

Diagnosis of Relapsed Burkitt's Lymphoma in a Urine Sample: an Unusual "FISHing" Expedition.

Sarid N, Kay S, Angel A, Trakhtenbrot L, Amit O, Herishanu Y, Perry C.

Isr Med Assoc J. 2015 Oct;17(10):648-9. No abstract available.

12.

Management of Hematologic Malignancies: Special Considerations in Pregnant Women.

Amit O, Barzilai M, Avivi I.

Drugs. 2015 Oct;75(15):1725-38. doi: 10.1007/s40265-015-0464-0. Review.

PMID:
26416583
13.
14.

Real-time analysis of the inside-out regulation of lymphocyte function-associated antigen-1 revealed similarities to and differences from very late antigen-4.

Chigaev A, Smagley Y, Zhang Y, Waller A, Haynes MK, Amit O, Wang W, Larson RS, Sklar LA.

J Biol Chem. 2011 Jun 10;286(23):20375-86. doi: 10.1074/jbc.M110.206185. Epub 2011 Apr 22.

15.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G; PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

PMID:
21435858
16.

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.

Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, Burger HU.

Eur J Cancer. 2011 Aug;47(12):1772-8. doi: 10.1016/j.ejca.2011.02.013. Epub 2011 Mar 21.

PMID:
21429737
17.

Blinded independent central review of the progression-free survival endpoint.

Amit O, Bushnell W, Dodd L, Roach N, Sargent D.

Oncologist. 2010;15(5):492-5. doi: 10.1634/theoncologist.2009-0261. No abstract available.

18.

Unconventional journals: protect nonconformists.

Amit OS.

Science. 2010 Apr 23;328(5977):427. doi: 10.1126/science.328.5977.427-b. No abstract available.

PMID:
20413474
19.

Abstract mathematics should be added to the pre-medical curriculum.

Amit OS.

Med Hypotheses. 2010 Aug;75(2):272. doi: 10.1016/j.mehy.2010.03.027. Epub 2010 Apr 14. No abstract available.

PMID:
20395060
20.

Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation.

Chigaev A, Waller A, Amit O, Halip L, Bologa CG, Sklar LA.

J Biol Chem. 2009 May 22;284(21):14337-46. doi: 10.1074/jbc.M901178200. Epub 2009 Feb 27.

21.

Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affinity: a possible mechanism for cell de-adhesion.

Chigaev A, Waller A, Amit O, Sklar LA.

BMC Immunol. 2008 Jun 5;9:26. doi: 10.1186/1471-2172-9-26.

22.

Graphical approaches to the analysis of safety data from clinical trials.

Amit O, Heiberger RM, Lane PW.

Pharm Stat. 2008 Jan-Mar;7(1):20-35.

PMID:
17323410
23.

Sgs1 regulates gene conversion tract lengths and crossovers independently of its helicase activity.

Lo YC, Paffett KS, Amit O, Clikeman JA, Sterk R, Brenneman MA, Nickoloff JA.

Mol Cell Biol. 2006 Jun;26(11):4086-94.

24.

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

Rennard SI, Schachter N, Strek M, Rickard K, Amit O.

Chest. 2006 Jan;129(1):56-66.

PMID:
16424413
25.

Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging.

Gu S, Liu Z, Pan S, Jiang Z, Lu H, Amit O, Bradbury EM, Hu CA, Chen X.

Mol Cell Proteomics. 2004 Oct;3(10):998-1008. Epub 2004 Jul 28.

26.

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK.

Am J Respir Crit Care Med. 2003 Oct 15;168(8):976-82. Epub 2003 Jun 19.

PMID:
12816740
27.

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.

Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC; International Study Group.

Lancet. 2001 Jul 28;358(9278):265-70.

PMID:
11498212
28.

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.

Goldberg MR, Lo MW, Christ DD, Chiou R, Furtek CI, Amit O, Carides A, Biollaz J, Piguet V, Nussberger J, Brunner HR.

Clin Pharmacol Ther. 1997 Jan;61(1):59-69.

PMID:
9024174

Supplemental Content

Support Center